In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Januvia: Defining Primary-Care Success and Risk

Executive Summary

Januvia's fast development and successful launch exemplifies Merck's new biomarker-based R&D operation and its focused "one Merck" strategy. But the drug also provides an ideal case study of why doing everything right in primary care brings with it extraordinary risks: the key elements of Januvia's success -- blazing speed through development and the extraordinary safety profile on which its commercial triumph depends -- also define its most dangerous commercial liabilities.
Advertisement

Related Content

Blow the Launch -- Doom the Product
Continuous Glucose Monitoring: A Revolution Powered by DexCom
Taking Aim at Diabetes
Novo Nordisk: Riding High on Diabetes
Amgen's Biotech Shopping Spree
Exubera's Problem: It's Still Just Insulin
CEO Interview: Novartis' Dan Vasella
NicOx's Naproxcinod: Hitting the NSAID Sweet Spot?
Pharma's High Hopes for Diabetes Drugs Revived
Positioning Acomplia: Has the Drug Arrived Before the Disease?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002914

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel